Millennium Management
PPBT

Millennium Management’s Purple Biotech PPBT Stock Holding History

Millennium Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-107
Closed -$14.3K – 6388
2024
Q1 		$14.3K Buy
+107
New +$15.3K ﹤0.01% 5867
2020
Q3 		– Sell
-20
Closed -$45K – 4738
2020
Q2 		$45K Buy
+20
New +$19.7K ﹤0.01% 4055

Other funds holding PPBT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WAOI
Wealth Advisors of Iowa West Des Moines, Iowa $369M AUM 18.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Millennium Management's PPBT Position: Q2 2024 in Review

Millennium Management sold out of Purple Biotech (PPBT) in Q2 2024, closing a stake of 107 shares — an estimated $14.3K sold.

Millennium Management first reported a position in PPBT in Q2 2020 and held it in 2 quarters. The position peaked at $45K in Q2 2020. 19 funds tracked by Wall St. Rank hold PPBT as of Q2 2024.

  • Millennium Management reported no remaining Purple Biotech position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 107 Purple Biotech shares in Q2 2024, an estimated $14.3K.
  • Millennium Management first reported a position in Purple Biotech in Q2 2020 and held it in 2 quarters.
  • Millennium Management's Purple Biotech position peaked at $45K in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.